# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

> **NCT05662033** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 93 (actual)

## Conditions studied

- Inflammatory Diseases

## Interventions

- **DRUG:** AZD6793
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05662033
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-05
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-10-29
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662033, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05662033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*